Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Southern Denmark
Odense, DinamarcaPublicacións en colaboración con investigadores/as de University of Southern Denmark (30)
2024
-
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
ESMO Open, Vol. 9, Núm. 2
-
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock
New England Journal of Medicine, Vol. 390, Núm. 15, pp. 1382-1393
-
Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up
The Lancet, Vol. 404, Núm. 10457, pp. 1019-1028
2023
-
Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies
Journal of the American Heart Association, Vol. 12, Núm. 12, pp. e027657
-
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599
-
Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022
Endoscopy, Vol. 55, Núm. 1, pp. 58-95
2022
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies
Neuro-oncology, Vol. 24, Núm. 9, pp. 1408-1422
2021
-
A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets
Journal of Personalized Medicine, Vol. 11, Núm. 6
-
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1139-1149
-
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
British Journal of Haematology, Vol. 194, Núm. 1, pp. 132-139
-
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica, Vol. 106, Núm. 6, pp. 1725-1732
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
-
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale
Gerontology, Vol. 66, Núm. 5, pp. 447-459
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2018
-
Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography
Journal of Proteome Research, Vol. 17, Núm. 3, pp. 1172-1182
2017
-
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Obstetrical and Gynecological Survey
2016
-
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Science Translational Medicine, Vol. 8, Núm. 341